Curis (CRIS) Reports Q3 Loss, Beats Revenue Estimates

Curis (CRIS) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of$ 0.62. This compares to a loss of $1.7 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +20.97%. A quarter ago, it was expected that this drug developer would post a loss of$ 1.99 per share when it actually produced a loss of $0.68, delivering a surprise of +65.83%.Over the last four quarters, the company has surpasse ...